First Time Loading...

Sio Gene Therapies Inc
NASDAQ:SIOX

Watchlist Manager
Sio Gene Therapies Inc Logo
Sio Gene Therapies Inc
NASDAQ:SIOX
Watchlist
Price: 0.478 USD 1.7%
Updated: May 20, 2024

Sio Gene Therapies Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sio Gene Therapies Inc
Income from Continuing Operations Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Sio Gene Therapies Inc
NASDAQ:SIOX
Income from Continuing Operations
-$28.8m
CAGR 3-Years
24%
CAGR 5-Years
35%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$6B
CAGR 3-Years
5%
CAGR 5-Years
2%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$456m
CAGR 3-Years
19%
CAGR 5-Years
-40%
CAGR 10-Years
-21%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$3.8B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
$4B
CAGR 3-Years
13%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$3.9B
CAGR 3-Years
-1%
CAGR 5-Years
10%
CAGR 10-Years
26%

See Also

What is Sio Gene Therapies Inc's Income from Continuing Operations?
Income from Continuing Operations
-28.8m USD

Based on the financial report for Dec 31, 2022, Sio Gene Therapies Inc's Income from Continuing Operations amounts to -28.8m USD.

What is Sio Gene Therapies Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
35%

Over the last year, the Income from Continuing Operations growth was 53%. The average annual Income from Continuing Operations growth rates for Sio Gene Therapies Inc have been 24% over the past three years , 35% over the past five years .